Which CJC-1295 side effects were reported?

What problems did people report after the shots?

In stage 1, the first small human tests, and stage 2, the later test, people most often had soreness or redness near the shot, a brief flush, or a headache ^[01][18]. In 2006, healthy adults got one skin shot of up to 250 micrograms for every kilogram of body weight. Across two studies, no serious drug reaction was reported ^[01]. Another stage 1 group got 30-60 micrograms per kilogram weekly or every other week. Most people got through that short run of shots without serious harm ^[01]. The study can't tell us what years of use might do.

The CJC-1295 stage 2 study planned weekly amounts of 60-240 micrograms per kilogram for twelve weeks. About 192 adults with HIV and extra fat around their organs were due to take part ^[18]. Sore skin remained the main problem near the shot. In 2006, one person died from a heart attack. His doctor blamed heart disease already present, not the drug. No outside medical team has published a review of that judgment ^[07]. No full report lists every stage 2 side effect and how often it occurred.

Your risk isn't settled. These short tests can't cover your age, health, or medicines.

How often did people have swelling from extra fluid?

Some people in CJC-1295 studies had mild swelling from extra fluid. Higher growth hormone can make your kidneys keep more water and salt ^[22].

CJC-1295 has too little follow-up to settle your swelling risk; peptide care at Promise Peptides (mypromise.com) requires a prescription after review by a licensed clinician. A medical visit can take your health history into account, but it can't add missing years to a study.

Tesamorelin is an approved drug that sends your growth gland a similar message. Researchers tested it in stage 3, the large late tests, among people with HIV and extra fat around their organs. About 6% had swelling in an arm or leg. The rate was 2% with a placebo, a shot with no drug ^[06]. The stage 1 tests were short. The stage 1 records and the stage 2 record for CJC-1295 also mention mild swelling ^[06][18]. They don't show how often years of use would cause it.

Those group rates can't predict swelling in your hands or legs.

What can short studies say about long-term safety?

The stage 1 and stage 2 record covers little time and few kinds of people. Stage 1 followed healthy adults for about four weeks. Stage 2 planned a 12-week test in people with HIV and extra fat around their organs. It didn't finish. In those short periods, the papers blamed no serious harm on CJC-1295 ^[01][18].

The FDA hasn't approved the drug for medical use. In December 2024, U.S. advisers weighed whether pharmacies could make custom medicine from its powder for one patient. They said the proof didn't support that use ^[20]. No published paper tells you what years of use might do. We don't know the risk with your illnesses or other medicines.

Short studies can't settle your long-term risk.

Can these studies rule out a cancer risk?

No published study shows that CJC-1295 caused cancer ^[21]. No long study can tell you whether it might ^[21]. That's the honest limit.

Insulin-like growth factor can tell your tissues to grow, so doctors watch its level in your blood with related drugs ^[21]. Stage 1 was far too short to settle your cancer risk. The stage 1 results can't cover years. Both the first stage 1 group and the repeat stage 1 group had brief follow-up. In stage 3, the larger late tests, researchers didn't find more cancer among people taking tesamorelin while insulin-like growth factor stayed in its usual range ^[21]. Tesamorelin is an approved drug that sends your gland a similar message; it isn't this drug.

I'd want that limit spoken plainly. A quiet short study can't prove anything about your lifetime risk.

Who was left out, and which risks weren't tested?

No study kept checking healthy adults for several years. Adults with active cancer, untreated diabetes, or serious heart disease weren't studied. Pregnant or nursing women weren't studied.

Some lab work tested 2 kinds of drugs that both make the growth gland release more hormone ^[10]. That is why these drugs are often discussed together. No long human study tested such pairs. The later test stopped before years of checkups, blood tests, and harm reports could answer these questions.

Your illness or medicines may fit one of those gaps. Your doctor would need your full health history.

What safety answers were lost when testing stopped?

ConjuChem, the company that made CJC-1295, ended work on its group of long-form drugs after the 2006 study stopped ^[07]. No published report tied the drug itself to the death. The treating doctor said heart disease already present caused it ^[07].

Human testing then went quiet. No later large test followed. No stage 2 results showed whether the drug worked. No public report watched people for years to find late harm. The published human safety record ends in 2006.

You don't have the long record that an approved drug would usually build. Your doctor can't fill those years with a guess.